earnings
confidence high
sentiment neutral
materiality 0.60
Bio-Rad Q2 revenue up 2% to $652M; completes Stilla acquisition
BIO-RAD LABORATORIES, INC.
2025-Q2 EPS reported
$13.84
revenue$1,237,000,000
- Q2 2025 revenue $651.6M (+2.1% YoY); GAAP net income $317.8M vs loss $2,165.5M (prior year included Sartorius losses).
- Non-GAAP EPS $2.61 vs $3.11; non-GAAP operating income $88.6M vs $106.9M, reflecting margin compression.
- GAAP gross margin 53.0% vs 55.6%; non-GAAP gross margin 53.7% vs 56.4%, down on product mix and costs.
- Completed acquisition of Stilla Technologies, expanding digital PCR portfolio with QX Continuum and QX700 systems.